证券代码：688177 证券简称：百奥泰 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《百奥泰生物制药股份有限公司章程》《百奥泰生物制 药股份有限公司股东会议事规则》等相关规定，百奥泰生物制药股份有限公司（以 下简称"公司"）特制定本次股东会会议须知： 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益，请出 席股东会的股东或其代理人或其他出席者准时到达会场签到确认参会资格。会议 开始后，会议登记应当终止，由会议主持人宣布现场出席会议的股东和代理人人 数及所持有的表决权数量。 三、会议按照会议通知上所列顺序审议、表决议案。 百奥泰生物制药股份有限公司 目 录 百奥泰生物制药股份有限公司 2025 年第二次临时股东会 百奥泰生物制药股份有限公司 四、股东及股东代理人参加股东会依法享有发言权、质询权、表决权等权利。 股东及股东代理人参加股东会应认真履行其法 ...

Investment Rating - The report maintains an "Optimistic" rating for the industry [7][71]. Core Insights - The report highlights the intensive disclosure of company performances, with a focus on companies that exceed expectations. It emphasizes the upcoming World Lung Cancer Conference (WCLC) and the importance of monitoring related company data [6][70]. - The report notes a significant increase in the medical device sector and mentions the approval of new treatments by regulatory bodies, indicating a positive trend in the pharmaceutical and medical device industries [2][16]. Industry News - The National Healthcare Security Administration issued a temporary management method for disease-based payment, which includes budget management and payment standards [16]. - Semaglutide received FDA approval for treating MASH, showcasing advancements in drug approvals [16]. Company Announcements - **Hengrui Medicine** reported a revenue of approximately 15.76 billion yuan for the first half of 2025, a year-on-year increase of 15.88%, and a net profit of approximately 4.45 billion yuan, up 29.67% [25]. - **Baili Tianheng** announced a significant drop in revenue but received breakthrough therapy designation from the FDA for its drug targeting advanced non-small cell lung cancer [28]. - **Rongchang Bio** received breakthrough therapy designation for its drug RC148 for non-small cell lung cancer and signed a licensing agreement [29]. - **Baiyao Tai** reported a revenue of approximately 441.89 million yuan, a year-on-year increase of 9.84%, and received EMA approval for Usymro® [30]. Market Review - The Shanghai Composite Index rose by 2.85%, while the pharmaceutical and biological sector increased by 1.85% during the week of August 15-21, 2025 [5][59]. - The industry’s price-to-earnings ratio (TTM) was reported at 31.23 times, with a valuation premium of 154% compared to the CSI 300 index [5][63]. Weekly Strategy - The report suggests focusing on companies with performance exceeding expectations during the earnings disclosure period and highlights the potential benefits from policy support for innovative drugs and medical devices [6][70].

Core Viewpoint - The company has signed a licensing and commercialization agreement with STADA for its BAT1806 (Tocilizumab) injection, granting STADA exclusive commercialization rights in several regions, which is expected to positively impact the company's future performance [2][4][14]. Agreement Summary - The agreement allows STADA to commercialize BAT1806 in the EU, Switzerland, the UK, parts of Europe, the MENA region, and CIS countries [2][10]. - The total transaction amount can reach up to €136 million, including an upfront payment of €8.5 million and milestone payments not exceeding €127.5 million, along with a percentage of net sales as revenue sharing [2][11][12]. Agreement Conditions - The agreement will take effect after approval by the company's shareholders and will last for an initial period of 15 years, automatically extending for 2 years unless either party provides written notice to terminate [3][13]. - The company will be responsible for the research, production, and supply of BAT1806, while STADA will handle its commercialization [10][14]. Impact on Company Performance - The signing of this agreement is expected to enhance the company's global commercialization and profitability capabilities [4][15]. - The collaboration is anticipated to leverage international advanced research, production quality control, and commercial promotion, thereby improving the company's core competitiveness [14].

证券代码：688177 证券简称：百奥泰 公告编号：2025-058 百奥泰生物制药股份有限公司 关于与 STADA 就 BAT1806（托珠单抗）注射液签 署授权许可与商业化协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ? 协议内容摘要： 本协议的签订预计将对公司未来业绩产生积极影响，有利于提升公司全球商 业化及盈利能力。 ? 协议履行中的重大风险及重大不确定性： 详见本公告之"五、协议履行的风险分析"。 一、 审议程序情况 百奥泰于 2025 年 8 月 20 日召开公司第三届董事会第二次会议，审议通过了 《关于就 BAT1806（托珠单抗）签署授权许可与商业化协议的议案》，本次签 署授权协议事项不属于关联交易和重大资产重组事项，根据《上海证券交易所科 创板股票上市规则》及公司章程等相关规定，本议案尚需提交公司股东会审议。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）与 STADA Arzneimittel AG （以下简称"STADA"）签署授权许可与商业化协议，将公司的 ...

百奥泰表示，本次协议的签署，旨在将公司研发成果通过商业合作及许可授权的方式快速转化为公司效 益，本次公司与STADA的合作，可以将国际先进的研发、生产质控、技术提升、临床应用及商业推广 等方面的优势进行有机结合，为公司的全球策略创造有利条件，对提升公司核心竞争力具有良好的推动 作用。 公告显示，此次交易首付款及里程碑款总金额最高至1.36亿欧元，其中包括850万欧元首付款、累计不 超过1.275亿欧元里程碑付款，以及净销售额的两位数百分比作为收入分成。 北京商报讯（记者 丁宁）8月21日早间，百奥泰（688177）发布公告称，公司与STADA Arzneimittel AG （以下简称"STADA"）签署授权许可与商业化协议，将公司的BAT1806（托珠单抗）注射液在欧盟、 瑞士、英国、其它部分欧洲国家、部分中东与北非地区（MENA）和部分独立国家联合体（CIS）国家 市场的独占的产品商业化权益有偿许可给STADA。 ...

百奥泰公告，公司与STADA签署授权许可与商业化协议，将BAT1806（托珠单抗）注射液在欧盟、瑞 士、英国、部分欧洲国家、中东与北非地区和独立国家联合体国家市场的独占商业化权益有偿许可给 STADA。交易金额包括850万欧元首付款、累计不超过1.27亿欧元里程碑付款，以及净销售额的两位数 百分比收入分成。协议生效后，预计将对公司未来业绩产生积极影响。 ...